20 scheduled drug formulations cleared for discontinuation amid weak demand and competition

The National Pharmaceutical Pricing Authority has approved 20 Form-IV intimations for discontinuation of scheduled formulations for FY 2025-26. The reasons cited include low or no market demand, declining market share, availability of competing products, portfolio optimisation and difficulties in sourcing APIs.

Send an email and you will receive our newsletters.